A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab monotherapy or placebo as adjuvant therapy. This study will be conducted in patients with HCC who are at high risk of recurrence after curative hepatic resection or ablation.
Inclusion Criteria:
Exclusion Criteria:
Dakahlia, 35516, Egypt
Shebeen El Kom, 32511, Egypt
Tricase, Lecce, 73039, Italy
Kurume-shi, 830-0011, Japan
Mitaka-shi, 181-8611, Japan
Musashino-shi, 180-8610, Japan
Osakasayama-shi, 589-8511, Japan
Shinagawa-ku, 142-8666, Japan
Shinjuku-ku, 160-0023, Japan
Shinjuku-ku, 162-8655, Japan
Shiwa-gun, 028-3695, Japan
Takasaki-shi, 370-0829, Japan
Yunlin, 640, Taiwan
Hochiminh, 70000, Vietnam